Bringing Insights to Life

Interpace Biosciences® (IDXG) is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer.

Learn More

IMPORTANT INFORMATION

Specimens and Orders for PancraGEN® and Fluid Chemistry
Testing Will Not Be Accepted After February 7, 2025.

Interpace will continue to offer ThyGeNEXT®+ThyraMIR®v2 without interruption.

View Details

Latest News

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results

Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq
View all news

Sign up for Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today

Stock Information

Day Range
52 Week Range
View Investor Relations